IQIRVO®
elafibranor

IPSEN

This is a promotional material created by Ipsen and is intended for UK HCPs only

HomeZone PLUS
Home care in your hands

Supporting primary biliary cholangitis (PBC) patients prescribed IQIRVO (elafibranor) with the option of home delivery

IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.[1]

IQIRVO Availability

You may provide IQIRVO to patients via the following channels:

- Patients can receive their tablets directly at home, with delivery arranged through Sciensus Pharma Services Ltd. (Sciensus), or Lloyds Clinical Ltd.
- Patients can pick up their tablets from the hospital pharmacy, with delivery managed via wholesaler AAH Pharmaceuticals Ltd. (AAH).

Patients also have the flexibility to switch between these options at any time, starting with one channel and moving to the other based on their needs.

For delivery to hospital pharmacy, IQIRVO is available to order only directly from wholesaler AAH .

Placing an order

To place an IQIRVO order to your hospital pharmacy, please order through the AAH account. If you do not have an account, you can request this at: https://www.aah.co.uk/s/opening-an-aah-account

Prescribing Information and Adverse Event Reporting can be accessed by scanning the QR code on the last page. IQIRVO (elafibranor) has a conditional marketing authorisation.

IQV-UK-000985
Date of prep: October 2026

HomeZonePLUS: Supporting access to treatment

For those patients who opt for home delivery, Ipsen is proud to offer HomeZonePLUS, a homecare service designed to provide patients with the flexibility of receiving their medication at a time and location that suits them.

HomeZonePLUS delivers IQIRVO directly to your patients through the homecare providers Sciensus and Lloyds.

Eligibility for HomeZonePLUS IQIRVO

This service is available to all NHS patients with a validated NHS prescription for IQIRVO.

Enrolling Patients into HomeZonePLUS

HCPs can initate patients onto IQIRVO HomeZonePLUS in a few simple steps:

Complete Trust homecare approvals and amend the Sciensus or Lloyds homecare Service Level Agreement (SLA) to include IQIRVO.

Submit an IQIRVO patient registration form AND the validated prescription form to Sciensus or Lloyds.

Sciensus and Lloyds will:

- Register the patient for the homecare service.
- Contact the patient to agree on a delivery schedule, usually within 5 days of registration.

Timeline

The entire process can take up to 10 working days. For patients requiring immediate treatment, it is recommended that initial medication is obtained directly via the hospital pharmacy.

Delivery Cycle

The standard delivery cycle is every 12 weeks. However, this may be adjusted to 4, 16, or 24 weeks depending on patient needs and NHS requirements.

IQIRVO Key Product Information[1]

- **Strength:** 80 mg film-coated tablets
- **Dose:** 1 Tablet per day, with no dose adjustment required in eligible patients. Can be taken with or without food.
- **Pack Size:** 30
- **Product Code:** 1076637
- **PIP Code:** 434 3901

For more details, refer to the full Prescribing Information.

Contact Information

If you have any questions regarding home delivery or IQIRVO, please contact your Ipsen Key Account Manager. Alternatively, you can contact Ipsen Customer Services **[custservuk@ipsen.com]**

Patient Support Materials

For your patients who have been prescribed IQIRVO, please refer them to Ipsen's patient support website, which can be accessed by visiting https://www.ipsen-hub.co.uk/primary-biliary-cholangitis/.

Prescribing Information and Adverse Event Reporting can be accessed by scanning the QR code or visiting www.emcpi.com/pi/45262

Abbreviations:
HCP, healthcare professional;
NHS, National Health Service;
PBC, primary biliary cholangitis;
SLA, service level agreement;
UDCA, ursodeoxycholic acid.

References:
1. IQIRVO, UK Summary of Product Characteristics.

IQV-UK-000985
Date of prep: October 2026